2 completed, 2 terminated, 1 recruiting, 1 unknown. 3 Phase 2, 2 Phase 3, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Severe combined immunodeficiency with sensitivity to ionizing radiation: new trials by email Literature Review of Severe combined immunodeficiency with sensitivity to ionizing radiation trials Research Report on Severe combined immunodeficiency with sensitivity to ionizing radiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) ARTEGENE drug product - Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 7 | 2023-07-19 | 2026-03-27 |
| A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo - Ulcerative Colitis | Phase 2 | Completed | Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 178 | 2021-07-14 | 2026-09-01 |
| MR-target Biopsy vs. TRUS-biopsy in Men With Suspicious Prostate Cancer Artemia - Prostate Cancer | Not applicable | Unknown | Asan Medical Center | 300 | 2020-03-23 | 2020-03-25 |
| ARTEMIS Peanut Allergy In Children AR101 powder provided in capsules & sachets, Placebo powder provided in capsules & sachets - Peanut Allergy | Phase 3 | Completed | Aimmune Therapeutics, Inc. | 175 | 2017-06-12 | 2021-08-03 |
| Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Placebo, Amatuximab, Pemetrexed - Mesothelioma, Malignant | Phase 2 | Terminated | Morphotek | 124 | 2015-11-03 | 2020-03-17 |
| Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters USL261, Placebo - Epilepsy | Phase 3 | Terminated | UCB Biopharma S.P.R.L. | 292 | 2011-06-01 | 2019-10-10 |
Colitis, Ulcerative (1) · Epilepsy (1) · Hypersensitivity (1) · Mesothelioma, Malignant (1) · Peanut Hypersensitivity (1) · Prostatic Neoplasms (1) · Severe Combined Immunodeficiency (1) · Xeroderma Pigmentosum, Complementation Group F (1)
Immune System Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Adenoma (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Colitis (1) · Colonic Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Digestive System Diseases (1) · Food Hypersensitivity (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Genetic Diseases, Inborn (1)
Capsules (1) · Cisplatin (1) · Pemetrexed (1) · amatuximab (1)
Aimmune Therapeutics, Inc. (1) · Asan Medical Center (1) · Assistance Publique - Hôpitaux de Paris (1) · Morphotek (1) · Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · UCB Biopharma S.P.R.L. (1)
France (4) · Italy (4) · Australia (3) · Germany (3) · United Kingdom (3) · United States (3) · Canada (2) · Hungary (2) · Israel (2) · Poland (2) · Spain (2) · Belgium (1) · Czechia (1) · Georgia (1) · Ireland (1)
Chantal Lagresle-Peyrou, MD (1) · In Gab Jeong, MD, PhD (1)
PMID 31140596, PMID 32702315, PMID 34320250, PMID 34389504, PMID 36410152, PMID 36915184, PMID 39321363
2014 (1), 2019 (1), 2023 (1)